PRQR NASDAQ
ProQR Therapeutics N.V.
1W: -0.6%
1M: -23.7%
3M: -4.7%
YTD: -17.6%
1Y: -24.1%
3Y: +18.8%
5Y: -79.0%
$1.64
+0.01 (+0.31%)
Weekly Expected Move ±6.4%
$1
$2
$2
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$15M
-19.2% ▼
5Y CAGR: +71.5%
Gross Profit
$13M
-32.9% ▼
5Y CAGR: +65.3%
Operating Income
-$42M
-38.3% ▼
Net Income
-$41M
-45.9% ▼
EPS (Diluted)
$-0.38
-11.8% ▼
EBITDA
-$40M
-64.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $1M | $4M | $7M | $19M | $15M |
| YoY Growth | +0.0% | +198.2% | +61.4% | +190.2% | -19.2% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $3M |
| Gross Profit | $1M | $4M | $7M | $19M | $13M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 83.0% |
| R&D Expenses | $42M | $51M | $25M | $36M | $41M |
| SG&A Expenses | $17M | $19M | $16M | $14M | $14M |
| Operating Expenses | $59M | $69M | $38M | $49M | $55M |
| Operating Income | -$57M | -$65M | -$32M | -$30M | -$42M |
| Operating Margin | -4285.4% | -1813.0% | -489.1% | -161.2% | -275.9% |
| Interest Expense | $3M | $5M | $1M | $1M | $866K |
| Income Before Tax | -$61M | -$64M | -$28M | -$28M | -$41M |
| Tax Expense | $117K | $96K | -$78K | -$197K | $18K |
| Net Income | -$61M | -$64M | -$28M | -$28M | -$41M |
| Net Margin | -4549.8% | -1792.5% | -431.7% | -146.9% | -265.2% |
| EPS (Diluted) | $-0.96 | $-0.91 | $-0.35 | $-0.34 | $-0.38 |
| EBITDA | -$55M | -$56M | -$24M | -$24M | -$40M |
| Shares Outstanding | 64M | 72M | 81M | 82M | 105M |